These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10918508)

  • 1. Safety evaluation of immunomodulatory biopharmaceuticals: can we improve the predictive value of preclinical studies?
    Black LE; Green JD; Rener J; Dayan A; Cavagnaro JA; Spindler P; Bussiere JL; Bouchard P; Inoue T; Thomas PT; Essayan DM; Gillett NA; Hart TK; Hastings K; House RV; Latta D; Liminga U; Treacy G; Wierda D
    Hum Exp Toxicol; 2000 Apr; 19(4):205-7. PubMed ID: 10918508
    [No Abstract]   [Full Text] [Related]  

  • 2. Preclinical assessments of european union marketing authorisation applications for immunomodulatory biopharmaceuticals.
    Liminga U
    Hum Exp Toxicol; 2000 Apr; 19(4):257-60. PubMed ID: 10918519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview status of preclinical safety assessment for immunomodulatory biopharmaceuticals.
    Green JD; Black LE
    Hum Exp Toxicol; 2000 Apr; 19(4):208-12. PubMed ID: 10918509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thirty years of preclinical safety evaluation of biopharmaceuticals: Did scientific progress lead to appropriate regulatory guidance?
    Kooijman M; van Meer PJ; Moors EH; Schellekens H
    Expert Opin Drug Saf; 2012 Sep; 11(5):797-801. PubMed ID: 22861668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotoxicology of immunomodulators.
    Descotes J
    Dev Biol Stand; 1992; 77():99-102. PubMed ID: 1426677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and problems in preclinical assessment of immunomodulators.
    Masek K
    Dev Biol Stand; 1992; 77():103-9. PubMed ID: 1426649
    [No Abstract]   [Full Text] [Related]  

  • 7. Can host resistance assays be used to evaluate the immunotoxicity of pharmaceuticals?
    Wierda D
    Hum Exp Toxicol; 2000 Apr; 19(4):244-5. PubMed ID: 10918515
    [No Abstract]   [Full Text] [Related]  

  • 8. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
    Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
    Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonclinical safety assessment of vaccines and adjuvants.
    Wolf JJ; Kaplanski CV; Lebron JA
    Methods Mol Biol; 2010; 626():29-40. PubMed ID: 20099119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonhuman primates: their role in assessing developmental effects of immunomodulatory agents.
    Hendrickx AG; Makori N; Peterson P
    Hum Exp Toxicol; 2000 Apr; 19(4):219-25. PubMed ID: 10918511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacodynamic screening of the immunostimulant activity of products from the plant Solenostema argel (Del.) Hayne].
    Younis GM; Pavelescu M; Stănescu U; Grigorescu E
    Rev Med Chir Soc Med Nat Iasi; 1988; 92(1):59-60. PubMed ID: 3393765
    [No Abstract]   [Full Text] [Related]  

  • 12. Overview of global regulatory toxicology requirements for vaccines and adjuvants.
    Sun Y; Gruber M; Matsumoto M
    J Pharmacol Toxicol Methods; 2012 Mar; 65(2):49-57. PubMed ID: 22326278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometry in the preclinical development of biopharmaceuticals.
    Gossett KA; Narayanan PK; Williams DM; Gore ER; Herzyk DJ; Hart TK; Sellers TS
    Toxicol Pathol; 1999; 27(1):32-7. PubMed ID: 10367670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Summaries of round-table discussions.
    Hum Exp Toxicol; 2000 Apr; 19(4):213-8. PubMed ID: 10918510
    [No Abstract]   [Full Text] [Related]  

  • 15. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Means for enhancing the effectiveness of immunostimulants].
    Lazareva DN; Alekhin EK
    Farmakol Toksikol; 1987; 50(2):5-12. PubMed ID: 3556213
    [No Abstract]   [Full Text] [Related]  

  • 17. Immune modulator studies in primates: the utility of flow cytometry and immunohistochemistry in the identification and characterization of immunotoxicity.
    Lappin PB; Black LE
    Toxicol Pathol; 2003; 31 Suppl():111-8. PubMed ID: 12597438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathology in the preclinical development of biopharmaceuticals.
    Gillett NA; Chan CM
    Toxicol Pathol; 1999; 27(1):48-52. PubMed ID: 10367673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A preclinical study of ximedone].
    Izmaĭlov SG; Gorbunov SM; Izmaĭlov GA; Zaikonnikova IV; Reznik VS; Abdrakhmanova NG; Pashkurov NG; Kedrin MIu; Gerasimova MKh; Garaev VN; Izmaĭlov AG; Podushkina IV; Evranova GB; Muslinkin AA
    Antibiot Khimioter; 1999; 44(8):12-7. PubMed ID: 10494385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New nonspecific means for preventing and combatting upper respiratory infections].
    Gheorghe V; Cucu M; Manea M; Andronache E
    Sante Publique (Bucur); 1987; 30(3):215-30. PubMed ID: 3455029
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.